

**Date:** 5<sup>th</sup> November, 2022

To,  
BSE Limited  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai - 400 001

Dear Sir / Madam,

**Sub: Submission of Unaudited Financial Results for the Quarter and Half Year ended on 30<sup>th</sup> September, 2022 along with Limited Review Report**

**Ref: Security Id: EARUM / Code: 542724**

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Unaudited Financial Results for the quarter and half year ended on 30<sup>th</sup> September, 2022 along with Limited Review Report.

Please take note of the same and oblige.

For, **Earum Pharmaceuticals Limited**

**Bhumishth Patel**  
**Director**  
**02516641**

**EARUM PHARMACEUTICALS LTD. CIN:L24230GJ2012PLC071299**

G-1, Ground Floor ,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

UNAUDITED BALANCE SHEET AS AT 30th SEPTEMBER, 2022

Particulars		As at 30th September	As at 31st March
		2022	2022 (Audited)
		Rs. (In Lacs)	Rs. (In Lacs)
<b>I.</b>	<b><u>ASSETS</u></b>		
	<b>Non-Current Assets</b>		
<b>1</b>	(a) Fixed Assets	53.22	58.06
	(i) Tangible Assets		-
	(ii) Intangible Assets		-
	(iii) Capital Work-In-Progress		-
	(iv) Intangible Assets under Development		-
	<b>Total Fixed Assets</b>	<b>53.22</b>	<b>58.06</b>
	(b) Non-Current Investments	-	-
	(c) Deferred Tax Assets (Net)	-	-
	(d) Long-Term Loans and Advances	-	-
	(e) Other Non-Current Assets	-	-
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments		
	(b) Inventories	1,132.44	1,224.90
	(c) Trade Receivables	1,518.28	1,504.26
	(d) Cash and Cash Equivalents	29.98	5.30
	(e) Short-Term Loans and Advances	167.85	57.48
	(f) Other Current Assets	29.43	29.43
	<b>Total Current Assets</b>	<b>2,877.98</b>	<b>2,821.37</b>
	<b>TOTAL &gt;&gt;&gt;&gt;</b>	<b>2,931.20</b>	<b>2,879.43</b>
<b>II.</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>Shareholders Funds</b>		
	(a) Share Capital	1,233.58	1,233.58
	(b) Reserves and Surplus	478.92	438.94
	(c) Money Received Against Share Warrants	-	-
	<b>Total Shareholders Funds</b>	<b>1,712.50</b>	<b>1,672.52</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>	-	-
<b>3</b>	<b>Non-Current Liabilities</b>		
	(a) Long-Term Borrowings	-	-
	(b) Deferred Tax Liabilities (Net)	1.07	1.07
	(c) Other Long Term Liabilities	-	-
	(d) Long-Term Provisions	-	-
	<b>Total Non Current Liabilites</b>	<b>1.07</b>	<b>1.07</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short-Term Borrowings	873.99	873.99
	(b) Trade Payables	-	-
	i) Total Outstanding dues of micro enterprise and small enterprise		-
	i) Total Outstanding dues of creditors other than micro enterprise and small enterprise	84.53	120.60
	(c) Other Current Liabilities	156.15	108.29
	(d) Short-Term Provisions	102.96	102.96
	<b>Total Current Liabilites</b>	<b>1,217.63</b>	<b>1,205.84</b>
	<b>TOTAL &gt;&gt;&gt;&gt;</b>	<b>2,931.20</b>	<b>2,879.43</b>
	<b>See accompanying notes forming part of the Financial Statements</b>		

For, Earum Pharmaceuticals Limited

Bhumishth Patel  
Director  
DIN : 02516641  
Date : 05/11/2022  
Place : Ahmedabad

**EARUM PHARMACEUTICALS LTD. CIN:L24230GJ2012PLC071299**

G-1, Ground Floor ,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30 th SEPTEMBER, 2022**

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2022 (Unaudited)	30.06.2022 (Audited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)	30.09.2021 (Unaudited)	For the Period Ended 31st March 2022
	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)
I. Revenue from Operations	711.44	427.87	842.29	1139.31	1141.03	2,103.56
II Other Income	0.00	86.57	220.04	86.57	228.31	770.30
<b>Total Revenue (I + II)</b>	<b>711.44</b>	<b>514.44</b>	<b>1062.33</b>	<b>1,225.88</b>	<b>1,369.34</b>	<b>2,873.86</b>
<b>III. Expenses:</b>						
Purchases of material	665.44	415.66	388.29	1081.10	692.73	2,182.54
Changes in Inventories	35.04	57.41	98.18	92.45	426.22	321.47
Employee Benefits Expenses	0.30	0.18	0.66	0.48	2.15	4.10
Finance Costs	0.00	0	0.96	0.00	8.22	8.22
Depreciation and Amortization expense	2.46	2.38	4.97	4.84	8.12	11.82
Other Expenses	4.53	2.51	29.30	7.04	33.23	37.54
<b>Total Expenses</b>	<b>707.77</b>	<b>478.14</b>	<b>522.36</b>	<b>1,185.91</b>	<b>1,170.67</b>	<b>2,565.69</b>
<b>IV. Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>308.17</b>
V. Exceptional Items						
Prior Period Expenses						
<b>VI. Profit Before Extraordinary Items and Tax (V - VI)</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>308.17</b>
VIII. Extraordinary Items						
<b>IX. Profit before tax (VII- VIII)</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>308.17</b>
X Tax expense:						
(1) Current tax	0.00	-	0		0	85.76
(2) Deferred tax						
<b>XI Profit (Loss) for the period from continuing operations (VII- VIII)</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>222.41</b>
XII Other Comprehensive Income / (Loss)						
i) Items that will not be reclassified to profit and loss	-	-	-			-
ii) Items will be reclassified to profit and loss	-	-	-			-
<b>XV Total Comprehensive Income/(Loss)</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>222.41</b>
<b>XVI BALANCE BROUGHT FROM PREVIOUS YEAR</b>						
<b>XVII BALANCE CARRIED TO BALANCE SHEET</b>	<b>3.67</b>	<b>36.30</b>	<b>539.97</b>	<b>39.97</b>	<b>198.67</b>	<b>222.41</b>
<b>XVIII Details of equity Share Capital</b>						
Paid Up Equity Share Capital	1233.58	1233.58	1233.58	1233.58	1233.58	1233.58
Other Equity	0	0	0	0	0	438.94
Face Value of equity share Capital	2	2	2	2	2	2
<b>Earnings per equity share:</b>						
<b>(1) Basic</b>	<b>0.003</b>	<b>0.29</b>	<b>4.38</b>	<b>0.03</b>	<b>1.56</b>	<b>0.36</b>
<b>(2) Diluted</b>	<b>0.003</b>	<b>0.29</b>	<b>4.38</b>	<b>0.03</b>	<b>1.56</b>	<b>0.36</b>

**Notes:**

- These financial results were reviewed by the audit committee and thereafter have been approved by the board of directors at its meeting held on Saturday November 05, 2022. The Statutory Auditors have carried out Limited review of the financial results for the quarter and half year ended September 30, 2022.
- These audited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013
- IND AS 108 Relating to Segment wise reporting is not applicable as the Company operates in only One Primary segment i.e Pharmaceutical Trading
- Previous year/Half Year/quarter figures have been regrouped/rearranged wherever necessary.

For, Earum Pharmaceuticals Limited

Bhumishth Patel  
Director  
DIN : 02516641  
Date : 05/11/2022  
Place : Ahmedabad

**EARUM PHARMACEUTICALS LTD. CIN:L24230GJ2012PLC071299**

G-1, Ground Floor ,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

**UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2022**

	Half Year Ended 30th Sep '22	Half Year Ended 30th Sep '21
<b>Cash flows from operating activities</b>		
Profit before taxation	39.97	308.17
<b>Adjustments for:</b>		
Depreciation	4.84	11.82
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	-	8.22
Profit / (Loss) on the sale of property, plant & equipment	-	-
<b>Working capital changes:</b>		
(Increase) / Decrease in trade and other receivables	(14.02)	(436.96)
(Increase) / Decrease in inventories	92.47	321.45
(Increase) / Decrease in Short Term Loan & Advance	(110.37)	4.44
(Increase) / Decrease in Other Current Assets	-	-
Increase / (Decrease) in Trade payables	(36.07)	(8.82)
Increase / (Decrease) in Short term Provisions	-	64.80
Increase / (Decrease) in Other Current Liabilities	47.86	73.31
Cash generated from operations	24.68	346.43
Interest paid	-	(8.22)
Income taxes paid	-	(85.76)
Dividends paid	-	-
<b>Net cash from operating activities</b>	24.68	252.45
<b>Cash flows from investing activities</b>		
Business acquisitions, net of cash acquired	-	-
Purchase of property, plant and equipment	-	-
Proceeds from sale of equipment	-	6.20
Acquisition of portfolio investments	-	-
Investment income	-	-
<b>Net cash used in investing activities</b>	-	6.20
<b>Cash flows from financing activities</b>		
Proceeds from issue of share capital	-	-
Proceeds from long-term borrowings	-	(237.89)
Proceeds from Short-term borrowings	-	(21.31)
Payment of Share Application Money	-	-
Share Capital Issue With Security Premium	-	-
<b>Net cash used in financing activities</b>	-	(259.20)
<b>Net increase in cash and cash equivalents</b>	24.68	(0.55)
<b>Cash and cash equivalents at beginning of period</b>	5.30	5.85
<b>Cash and cash equivalents at end of period</b>	29.98	5.30

For, Earum Pharmaceuticals Limited

Bhumishth Patel

Director

DIN : 02516641

Date : 05/11/2022

Place : Ahmedabad



**J. M. PATEL & BROS.**

Chartered Accountants

E-mail : jmpatelca@yahoo.co.in

204, Harsh Avenue,  
Navjivan Press Road,  
Nr. Old High Court Crossing,  
AHMEDABAD-380 014.  
Phone : (079) 27541460

Ref. No. :

Date :

**LIMITED REVIEW REPORT OF EARUM PHARMACEUTICALS LIMITED**

Review Report to

To,

**The Board of Directors,**

**Earum Pharmaceuticals Limited**

**CIN : L24230GJ2012PLC071299**

**AHMEDABAD**

We have reviewed the accompanying statement of unaudited financial results of **Earum Pharmaceuticals Limited (CIN : L24230GJ2012PLC071299)** for the Quarter and half year ended **30<sup>th</sup> September, 2022**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement subject to state bank of india CC Accounts Rs. 8.74 Crores outstanding are inoperative and No provision for interest Rs. 42.30 Lakhs (Approx.) on SBI loan is not made into accounts.

**For J M PATEL & BROS.,**

*Chartered Accountants*

**FRN: 107707W**



**CA JASWANT M. PATEL**

*Partner*

**M. No. 030161**

**UDIN NO : 22030161BCECVH4444**

Place: Ahmedabad

Date: 05/11/2022

